OR WAIT null SECS
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
August 02, 2019
A risk-based approach to CMC enables drug sponsors to focus on clinical and manufacturing development paths.
As vaccines gain prominence within pharma, there is an expectation that specialized CDMO services will provide opportunities.
Pharmaceutical Technology Europe celebrates 30 years in publishing the latest insights, analysis, and developments of the bio/pharma industry.
The evolution of CDMOs has led to increased investment in new technologies, capabilities, and expertise.
To help customers succeed, CDMOs have moved away from the ‘fee-for-service’ model to offer flexible, full-service partnerships.
Complex and potent molecules demand greater technical and regulatory expertise to ensure safe handling.
August 01, 2019
A one-size-fits-all strategy is not the best approach for the development of a chemistry, manufacturing, and controls program.
Now that the first genetically modified cell therapies are being manufactured, the industry must move beyond “whatever works” to meet growing demand.
Does the pharmaceutical industry have adequate access to contained equipment, facilities, and infrastructure for the manufacture of highly potent APIs?
Key considerations when searching for an analytical service provider include workflow, hardware, and regulatory support.